Serum increase and liver overexpression of carbohydrate 19.9 antigen in patients with genetic haemochromatosis.
Open Access
- 1 August 1994
- Vol. 35 (8) , 1107-1111
- https://doi.org/10.1136/gut.35.8.1107
Abstract
CA 19.9 antigen is mainly secreted by biliary and pancreatic duct cells. Its metabolism could be modified in genetic haemochromatosis by iron accumulation within these cells. Therefore, CA 19.9 was assayed in the serum samples of 84 patients with genetic haemochromatosis before and after iron depletion and immunolocalised in the liver of 24 untreated genetic haemochromatosis cases. The study showed that serum CA 19.9 (N < 37 IU/l) was increased (SD) before treatment (41.2 (34)) when compared with after the venesection period (16 (12)), and correlated, before treatment, with the amount of iron excess, transaminases, fibrosis, and biliary iron deposits. Hepatic CA 19.9 was located within the cytoplasm of bile duct and cholangiolar cells. In conclusion, this study shows that a mild, reversible, and non-specific increase in serum CA 19.9 is common in genetic haemochromatosis patients and shows that this increase is related to iron excess, directly or through associated liver damage. The unexplained finding of a mild increase in serum CA 19.9 should lead, in a patient with no diagnosis, to the search for liver iron overload, and, in a patient with untreated genetic haemochromatosis, not to further diagnostic procedures unless this finding persists after completion of the venesection treatment.Keywords
This publication has 41 references indexed in Scilit:
- Prognostic Value of Serum CA 19–9 Levels in Pancreatic AdenocarcinomaAnnals of Surgery, 1992
- Tumour Markers CA 19-9 and CA 50 in Digestive Tract MalignanciesScandinavian Journal of Gastroenterology, 1992
- Pancreatoduodenal carcinoma: A clinicopathologic study of 304 patients and immunohistochemical observation for CEA and CA19‐9Journal of Surgical Oncology, 1991
- Tumor markers carcinoembryonic antigen, tissue polypeptide antigen, and carbohydrate antigen 19/9 in liver diseasesJournal of Surgical Oncology, 1988
- Prospective Evaluation of the Diagnostic Efficacy of CA 19–9 Assay as a Marker for Gastrointestinal CancersDigestion, 1986
- A clinical evaluation of carbohydrate antigen 19‐9 and carcinoembryonic antigen in patients with pancreatic carcinomaJournal of Surgical Oncology, 1985
- The clinical validity of circulating tumor-associated antigens CEA and CA 19-9 in primary diagnosis and follow-up of patients with gastrointestinal malignanciesJournal of Molecular Medicine, 1985
- Comparison of a new tumour marker, CA 19-9, with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases.Journal of Clinical Pathology, 1984
- The role of sialic acid in determining the life-span of circulating cells and glycoproteinsCellular and Molecular Life Sciences, 1976
- Measurement of Circulating Desialylated Glycoproteins and Correlation with Hepatocellular DamageJournal of Clinical Investigation, 1974